The Guardian view on weight-loss jabs and addiction: there is too much moralising about these remarkable medicines | Editorial

"Patients already using substances appeared about half as likely to suffer overdose or drug-related death if they were taking the jab as well. This is an exciting avenue for future research. These medicines work partly on satiation and reward centres in the brain. It is likely that problematic food and drug cravings share a similar biological basis, and next-generation medicines may be more powerful or more targeted to one or the other."

"To put it bluntly, drug addiction is seen as an illness in a way that obesity despite some progress is not. Ever since GLP-1 agonist drugs emerged, many have argued that using them for weight loss is a sort of cop-out an answer to a problem that should be addressed through willpower and strength of character."

"There are certainly downsides to GLP-1 agonists. They are expensive and have unpleasant side-effects, and additional rare but serious complications may still emerge a recent study suggested they carry an increased risk of vision loss."

Weight-loss medications, particularly GLP-1 agonists, demonstrate potential benefits beyond appetite suppression. Recent research on US veterans with diabetes indicates that patients using these drugs are approximately half as likely to experience overdose or drug-related death. These medicines function by affecting satiation and reward centers in the brain, suggesting that food and drug cravings may share similar biological pathways. Future generations of these medications could be specifically targeted toward addiction treatment. However, societal attitudes toward obesity differ significantly from those toward drug addiction, with many viewing weight loss as a personal responsibility rather than a medical condition. While these drugs offer promising therapeutic potential, they remain expensive, carry unpleasant side effects, and may pose rare but serious health risks.

Read at www.theguardian.com